Emerging trends in the evaluation and management of small cell prostate cancer

a clinical and molecular perspective

M. Francesca Monn, Liang Cheng

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor clinical outcomes. It can arise de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Current therapeutic interventions are based upon observations the PSCC responds similarly to small cell carcinoma of the lung. Standard treatment includes chemotherapy with cisplatin and etoposide, radiation therapy, and occasional extirpative management. Ongoing research into the molecular pathway behind the development of PSCC and potential interventions is resulting in the identification of multiple novel therapeutic targets. Areas covered: A review of contemporary literature was undertaken to evaluate the histology, pathogenesis, evolution, current and novel treatment regimens, and upcoming methods of diagnosis of PSCC. To this end a literature search using terms, ‘prostate small cell carcinoma’, ‘neuroendocrine prostate cancer’, and derivations thereof was performed with a thorough review of the current literature. Expert commentary: Among current studies, AURKA inhibitors and PAPR1 inhibitors are exciting potential targets with early studies suggesting significant benefit. Continued research into the molecular underpinnings of PSCC is necessary to identify novel targets for early identification of patients with PSCC and to develop optimal treatment regimens.

Original languageEnglish (US)
Pages (from-to)1029-1037
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume16
Issue number10
DOIs
StatePublished - Oct 2 2016

Fingerprint

Small Cell Carcinoma
Prostatic Neoplasms
Prostate
Aurora Kinase A
Therapeutics
Small Cell Lung Carcinoma
Etoposide
Research
Cisplatin
Histology
Adenocarcinoma
Radiotherapy
Drug Therapy

Keywords

  • molecular genetics
  • neuroendocrine differentiation
  • prognosis and treatment
  • Prostate
  • small cell prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Emerging trends in the evaluation and management of small cell prostate cancer : a clinical and molecular perspective. / Monn, M. Francesca; Cheng, Liang.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 10, 02.10.2016, p. 1029-1037.

Research output: Contribution to journalReview article

@article{ce9da8072b9b455abe3b8c9d9ce91c1e,
title = "Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective",
abstract = "Introduction: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor clinical outcomes. It can arise de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Current therapeutic interventions are based upon observations the PSCC responds similarly to small cell carcinoma of the lung. Standard treatment includes chemotherapy with cisplatin and etoposide, radiation therapy, and occasional extirpative management. Ongoing research into the molecular pathway behind the development of PSCC and potential interventions is resulting in the identification of multiple novel therapeutic targets. Areas covered: A review of contemporary literature was undertaken to evaluate the histology, pathogenesis, evolution, current and novel treatment regimens, and upcoming methods of diagnosis of PSCC. To this end a literature search using terms, ‘prostate small cell carcinoma’, ‘neuroendocrine prostate cancer’, and derivations thereof was performed with a thorough review of the current literature. Expert commentary: Among current studies, AURKA inhibitors and PAPR1 inhibitors are exciting potential targets with early studies suggesting significant benefit. Continued research into the molecular underpinnings of PSCC is necessary to identify novel targets for early identification of patients with PSCC and to develop optimal treatment regimens.",
keywords = "molecular genetics, neuroendocrine differentiation, prognosis and treatment, Prostate, small cell prostate cancer",
author = "Monn, {M. Francesca} and Liang Cheng",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/14737140.2016.1226137",
language = "English (US)",
volume = "16",
pages = "1029--1037",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Emerging trends in the evaluation and management of small cell prostate cancer

T2 - a clinical and molecular perspective

AU - Monn, M. Francesca

AU - Cheng, Liang

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Introduction: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor clinical outcomes. It can arise de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Current therapeutic interventions are based upon observations the PSCC responds similarly to small cell carcinoma of the lung. Standard treatment includes chemotherapy with cisplatin and etoposide, radiation therapy, and occasional extirpative management. Ongoing research into the molecular pathway behind the development of PSCC and potential interventions is resulting in the identification of multiple novel therapeutic targets. Areas covered: A review of contemporary literature was undertaken to evaluate the histology, pathogenesis, evolution, current and novel treatment regimens, and upcoming methods of diagnosis of PSCC. To this end a literature search using terms, ‘prostate small cell carcinoma’, ‘neuroendocrine prostate cancer’, and derivations thereof was performed with a thorough review of the current literature. Expert commentary: Among current studies, AURKA inhibitors and PAPR1 inhibitors are exciting potential targets with early studies suggesting significant benefit. Continued research into the molecular underpinnings of PSCC is necessary to identify novel targets for early identification of patients with PSCC and to develop optimal treatment regimens.

AB - Introduction: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor clinical outcomes. It can arise de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Current therapeutic interventions are based upon observations the PSCC responds similarly to small cell carcinoma of the lung. Standard treatment includes chemotherapy with cisplatin and etoposide, radiation therapy, and occasional extirpative management. Ongoing research into the molecular pathway behind the development of PSCC and potential interventions is resulting in the identification of multiple novel therapeutic targets. Areas covered: A review of contemporary literature was undertaken to evaluate the histology, pathogenesis, evolution, current and novel treatment regimens, and upcoming methods of diagnosis of PSCC. To this end a literature search using terms, ‘prostate small cell carcinoma’, ‘neuroendocrine prostate cancer’, and derivations thereof was performed with a thorough review of the current literature. Expert commentary: Among current studies, AURKA inhibitors and PAPR1 inhibitors are exciting potential targets with early studies suggesting significant benefit. Continued research into the molecular underpinnings of PSCC is necessary to identify novel targets for early identification of patients with PSCC and to develop optimal treatment regimens.

KW - molecular genetics

KW - neuroendocrine differentiation

KW - prognosis and treatment

KW - Prostate

KW - small cell prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84988891254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988891254&partnerID=8YFLogxK

U2 - 10.1080/14737140.2016.1226137

DO - 10.1080/14737140.2016.1226137

M3 - Review article

VL - 16

SP - 1029

EP - 1037

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -